CABOMETYX®▼ (cabozantinib) is a prescription-only medicine indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
For more information on this product please visit the electronic Medicines Compendium (eMC) where you will find links to the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC)
You can also find out further information from your Healthcare Professional.
This information is intended for UK healthcare professionals only. Are you a UK healthcare professional?
Yes, I am a UK Healthcare professional No, I am not a UK Healthcare professional
Copyright © 2017 Ipsen Limited. CMX-UK-000711 Date of Preparation February 2018
Do you wish to continue?